The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of ERCC1 and RRM1 as prognostic biomarkers in urothelial cancer (UC) treated with adjuvant platinum and gemcitabine chemotherapy.
Lauren Christine Harshman
No relevant relationships to disclose
Gerold Bepler
Consultant or Advisory Role - Lilly
Other Remuneration - Genzyme
David I. Quinn
No relevant relationships to disclose
Jesse McKenney
No relevant relationships to disclose
Debra Hawes
No relevant relationships to disclose
Noah Simon
No relevant relationships to disclose
Sandy Srinivas
No relevant relationships to disclose
Tanya B. Dorff
No relevant relationships to disclose